BioSpace News Archive

Revalesio, announced that data from multiple clinical studies evaluating the company’s lead drug candidate RNS60, including a Phase 2 trial, are being presented as posters at the ALS/MND International Symposium held December 7-10, 2021.

SourceMark Medical, announced today its GPO contract for their ClearViz™ Video Laryngoscope system with Vizient, which provides solutions that help more than 50% of the nation’s acute providers and more than 20% of ambulatory care providers deliver high-value care to their patients.

Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), announced today that CoSara Diagnostics Pvt Ltd (“CoSara,” or the “JV”), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization (“CDSCO”) in India to manufacture and sell its SARAPLEX™ Flu A/Flu B/COVID-19 (ABC) RT-PCR test as an in vitro diagnostic (“IVD”).

Olympus Corporation, has clarified the direction of its medical business with the aim of achieving further growth and profitability by elevating the standard of care in targeted disease states.

Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapies, announced it has entered into a strategic collaboration agreement with AstraZeneca to develop and commercialize eplontersen, Ionis’ investigational antisense medicine for the treatment of transthyretin amyloidosis.

Aerie Pharmaceuticals, Inc. announced that Aerie and Santen have entered into an exclusive development and commercialization agreement for Rhopressa®/Rhokiinsa® 0.02% and Rocklatan®/Roclanda® 0.02%/0.005%.

GlaxoSmithKline plc and Vir Biotechnology, Inc. announced an update to preclinical data on bioRxiv1, a preprint server, demonstrating that sotrovimab, an investigational monoclonal antibody, retains in vitro activity against the full known Omicron spike protein, the new SARS-CoV-2 variant.

Vir Biotechnology, Inc. announced that Management will host a conference call at 8:30 am ET, Tuesday, December 7, 2021, to discuss new data that demonstrates sotrovimab retains activity against the full combination of mutations in the spike protein of the Omicron SARS-CoV-2 variant.

Galderma, the world’s largest independent dermatology company, announced that Maria Teresa “Tessa” Hilado will join its Advisory Committee, effective January 1, 2022.

Sino Biological, Inc. announced that it has launched a panel of research reagents for the newly identified Omicron variant of the SARS-COV-2 virus, which quickly raised concerns around the world because of the high number of mutations it carries, especially the 30-plus mutations on the Spike protein.